Some six years after the FDA approved Eli Lilly’s Retevmo to treat lung a | Six years after the FDA approved Eli Lilly’s ...

Only days after the surprise ouster of Sanofi CEO Paul Hudson, the executive roster shakeups at the French drug giant are continuing with the appointment of a new specialty care chief. | Serving on ...

The clamor for radioisotopes has continued into the new year, with Novartis inking a deal with radiopharmaceutical producer Niowave to supply the pharma giant with the specialized ingredient ...

But now, 13 years after the FDA initially blessed it for skin cancer, the U.S. regulator has approved Keytruda as a second- ...

As Novo Nordisk’s hotly anticipated Wegovy pill gets off to the races in the U.S., the company is making sure to cover its ...

Bayer has cooked up the next phase of its “See Your Risks” campaign, tapping Food Network star Jeff Mauro as its sous chef. ...

Mani Foroohar, M.D., of Leerink Partners, says that the decision reflects “how sharp the departure has been between the prior ...

After ending 2025 with a strong fourth quarter, AstraZeneca management has doubled down on its ambitious “$80 billion by 2030 ...

During the first six months of Maziar Mike Doustdar's tenure as Novo Nordisk's CEO, the company enjoyed a run of positive ...

Chinese prosecutors have brought formal charges against AstraZeneca and its former executives following investigations into alleged illegal patient data collection and importation of drugs. | Chinese ...

After Novo Nordisk projected yesterday that its revenue could decline by as much as 13% in 2026, its share price has ...

As the U.S. backpedals on its mRNA investment, Mexico is embracing the technology through a new manufacturing pact with ...